» Articles » PMID: 36735106

Lipid Nanoparticles for Nucleic Acid Delivery to Endothelial Cells

Overview
Journal Pharm Res
Specialties Pharmacology
Pharmacy
Date 2023 Feb 3
PMID 36735106
Authors
Affiliations
Soon will be listed here.
Abstract

Endothelial cells play critical roles in circulatory homeostasis and are also the gateway to the major organs of the body. Dysfunction, injury, and gene expression profiles of these cells can cause, or are caused by, prevalent chronic diseases such as diabetes, cardiovascular disease, and cancer. Modulation of gene expression within endothelial cells could therefore be therapeutically strategic in treating longstanding disease challenges. Lipid nanoparticles (LNP) have emerged as potent, scalable, and tunable carrier systems for delivering nucleic acids, making them attractive vehicles for gene delivery to endothelial cells. Here, we discuss the functions of endothelial cells and highlight some receptors that are upregulated during health and disease. Examples and applications of DNA, mRNA, circRNA, saRNA, siRNA, shRNA, miRNA, and ASO delivery to endothelial cells and their targets are reviewed, as well as LNP composition and morphology, formulation strategies, target proteins, and biomechanical factors that modulate endothelial cell targeting. Finally, we discuss FDA-approved LNPs as well as LNPs that have been tested in clinical trials and their challenges, and provide some perspectives as to how to surmount those challenges.

Citing Articles

Nanomedicines for Pulmonary Drug Delivery: Overcoming Barriers in the Treatment of Respiratory Infections and Lung Cancer.

Fernandez-Garcia R, Fraguas-Sanchez A Pharmaceutics. 2025; 16(12.

PMID: 39771562 PMC: 11677881. DOI: 10.3390/pharmaceutics16121584.


Better, Faster, Stronger: Accelerating mRNA-Based Immunotherapies With Nanocarriers.

Carvalho H, Fidalgo T, Acurcio R, Matos A, Satchi-Fainaro R, Florindo H Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024; 16(6):e2017.

PMID: 39537215 PMC: 11655444. DOI: 10.1002/wnan.2017.


Nanocarriers for targeted drug delivery in the vascular system: focus on endothelium.

Cong X, Zhang Z, Li H, Yang Y, Zhang Y, Sun T J Nanobiotechnology. 2024; 22(1):620.

PMID: 39396002 PMC: 11470712. DOI: 10.1186/s12951-024-02892-9.


Understanding nanoparticle-liver interactions in nanomedicine.

He Y, Wang Y, Wang L, Jiang W, Wilhelm S Expert Opin Drug Deliv. 2024; 21(6):829-843.

PMID: 38946471 PMC: 11281865. DOI: 10.1080/17425247.2024.2375400.


Strategies for Improved pDNA Loading and Protection Using Cationic and Neutral LNPs with Industrial Scalability Potential Using Microfluidic Technology.

Ottonelli I, Adani E, Bighinati A, Cuoghi S, Tosi G, Vandelli M Int J Nanomedicine. 2024; 19:4235-4251.

PMID: 38766661 PMC: 11102183. DOI: 10.2147/IJN.S457302.


References
1.
Stoltz J, Muller S, Kadi A, Decot V, Menu P, Bensoussan D . Introduction to endothelial cell biology. Clin Hemorheol Microcirc. 2007; 37(1-2):5-8. View

2.
Martin F, Murphy R, Cummins P . Thrombomodulin and the vascular endothelium: insights into functional, regulatory, and therapeutic aspects. Am J Physiol Heart Circ Physiol. 2013; 304(12):H1585-97. PMC: 7212260. DOI: 10.1152/ajpheart.00096.2013. View

3.
Maroney S, Mast A . Expression of tissue factor pathway inhibitor by endothelial cells and platelets. Transfus Apher Sci. 2008; 38(1):9-14. PMC: 2408687. DOI: 10.1016/j.transci.2007.12.001. View

4.
Rao L, Esmon C, Pendurthi U . Endothelial cell protein C receptor: a multiliganded and multifunctional receptor. Blood. 2014; 124(10):1553-62. PMC: 4155268. DOI: 10.1182/blood-2014-05-578328. View

5.
Neubauer K, Zieger B . Endothelial cells and coagulation. Cell Tissue Res. 2021; 387(3):391-398. PMC: 8975780. DOI: 10.1007/s00441-021-03471-2. View